Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-kB, on glioblastoma

Neuro-Oncology

Volumn 14, Issue 1, 2012, Pages 19-28

  Fukushima, Tsuyoshi ^a   Kawaguchi, Makiko ^a   Yorita, Kenji ^a   Tanaka, Hiroyuki ^a   Takeshima, Hideo ^a   Umezawa, Kazuo ^b   Kataoka, Hiroaki ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

DHMEQ; Glioblastoma; NF kB; RelA

Indexed keywords

DEHYDROXYMETHYLEPOXYQUINOMICIN; I KAPPA B; PROUROKINASE; TRANSCRIPTION FACTOR RELA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CELL GROWTH; CHEMOPROPHYLAXIS; CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; GLIOBLASTOMA; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; M PHASE CELL CYCLE CHECKPOINT; MALE; MICROVASCULATURE; MOUSE; NECROSIS; NONHUMAN; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BRAIN NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLOHEXANONES; GLIOBLASTOMA; HUMANS; MALE; MICE; MICE, NUDE; NF-KAPPA B; TRANSCRIPTION FACTOR RELA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856249399     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor168     Document Type: Article

References (35)

1. Khasraw M, Lassman AB. Advances in the treatment of malignant gliomas. Curr Oncol Rep. 2010;12:26-33.
2. Patrick A.B. IkB-NF-κB Structures: At the interface of inflammation control. Cell. 1998;95:729-731.
3. Rayet B, Gélinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999;18:6938-6947.
4. Wang H,Wang H, ZhangW, Huang HJ, Liao WS, Fuller GN. Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest. 2004;84:941-951. (Pubitemid 39025029)
5. Tsunoda K, Kitange G, Anda T. Expression of the constitutively activated RelA/NF-kappaB in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, and invasion. Brain Tumor Pathol. 2005;22:79-87. (Pubitemid 44576317)
6. Li L, Gondi CS, Dinh DH, Olivero WC, Gujrati M, Rao JS. Transfectionwith anti-p65 intrabody suppresses invasion and angiogenesis in glioma cells by blocking nuclear factor-kB transcriptional activity. Clin Cancer Res. 2007;13:2178-2190. (Pubitemid 46649888)
7. Smith D, Shimamura T, Barbera S, Bejcek BE. NF-kappaB controls growth of glioblastomas/astrocytomas. Mol Cell Biochem. 2008; 307:141-147.
8. Li J, Gong LY, Song LB, et al. Oncoprotein Bmi-1 renders apoptotic resistance to glioma cells through activation of the IKK-nuclear factor-kappaB Pathway. Am J Pathol. 2010;176:699-709.
9. Matsumoto N, Ariga A, To-e S, et al. Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett. 2000;10:865-869. (Pubitemid 30301582)
10. Umezawa K. Inhibition of tumor growth by NF-kappaB inhibitors. Cancer Sci. 2006;97:990-995. (Pubitemid 44322544)
11. Yamamoto M, Horie R, Takeiri M, Kozawa I, Umezawa K. Inactivation of nuclear kappa B components by covalent bincing of (-)- dehydroxymethylepoxyquinomicin to specific cysteine residues. J Mod Chem. 2008;51:5780-5788.
12. Ariga A, Mamekawa J, Matsumoto N, Inoue J, Umezawa K. Inhibition of tumor necrosis factor-a -induced nuclear translocation and activation of NF-κB by dehydroxymethylepoxyquinomicin. J Biol Chem. 2002; 277:27625-27630.
13. Kikuchi E, Horiguchi Y, Nakashima J, et al. Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice. Cancer Res. 2003;63:107-110. (Pubitemid 36070427)
14. Starenki DV, Namba H, Saenko VA. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res. 2004;10:6821-6829. (Pubitemid 39383030)
15. Matsumoto G, Namekawa J, Muta M. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: Antitumor and antiangiogenic potential in vivo. Clin Cancer Res. 2005;11:1287-1293. (Pubitemid 40175782)
16. Watanabe M, Ohsugi T, Shoda M, et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood. 2005;106:2462-2471. (Pubitemid 41510821)
17. Watanabe M, Dewan MZ, Okamura T, et al. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer. 2005;114:32-38. (Pubitemid 40194306)
18. Horiuchi K, Morioka H, Nishimoto K, et al. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ). Cancer Lett. 2008;272:336-344.
19. Dabaghmanesh N, Matsubara A, Miyake A, et al. Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation. Cancer Sci. 2009;100:737-746.
20. Lampiasi N, Azzolina A, D'Alessandro N, et al. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism. Mol Pharmacol. 2009;76: 290-300.
21. Wong JH, Lui VW, Umezawa K, et al. A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. Cancer Lett. 2010;287:23-32.
22. Kodaira K, Kikuchi E, Kosugi M, et al. Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines. Urology. 2010;75:805-812.
23. Dror R, Lederman M, Umezawa K, Barak V, Pe'er J, Chowers I. Characterizing the involvement of the nuclear factor-kappa B (NF-κB) transcription factor in uveal melanoma. Invest. Ophthalmol. Vis Sci. 2010;51:1811-1816.
24. Nuki Y, Uchinokura S, Miyata S, et al. Establishment and characterization of a new human glioblastoma cell line, NYGM. Hum Cell. 2004; 17: 145-150.
25. Moriyama T, Kataoka H, Seguchi K, et al. Establishment and characterization of a new human glioblastoma cell line (MGM-1) with highly motile phenotype. Hum Cell. 1997;10:105-109.
26. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System, 4th edn. Lyon, France: International Agency for Research on Cancer (IARC); 2007.
27. Fukushima T, Tezuka T, Shimomura T, Nakano S, Kataoka H. Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem. 2007;282: 18634-18644. (Pubitemid 47100243)
28. Uchinokura S, Miyata S, Fukushima T, et al. Role of hepatocyte growth factor activator (HGF activator) in invasive growth of human glioblastoma cells in vivo. Int J Cancer. 2006;118:583-592. (Pubitemid 43076006)
29. Nagaike K, Kawaguchi M, Naoki Takeda N, et al. Defect of hepatocyte growth factor activator inhibitor type 1/serine protease inhibitor, Kunitz type 1 (Hai-1/Spint1) leads to ichthyosis-like condition and abnormal hair development in mice. Am J Pathol. 2008;173:1464-1475.
30. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170:1445-1453. (Pubitemid 47339290)
31. Shirahata M, Oba S, Iwao-Koizumi K, et al. Using gene expression profiling to identify a prognostic molecular spectrum in gliomas. Cancer Sci. 2009;100:165-172.
32. Epinat JC, Gilmore TD. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene. 1999;18: 6896-6909.
33. Watanabe M, Nakashima M, Togano T, et al. Identification of the RelA domain responsible for action of a new NF-kappaB inhibitor DHMEQ. Biochem Biophys Res Commun. 2008;376:310-314.
34. Zhang R, Banik NL, Ray SK. Combination of all-trans retinoic acid and interferon-gamma suppressed PI3K/Akt survival pathway in glioblastoma T98G cells whereas NF-κB survival signaling in glioblastoma U87MG cells for induction of apoptosis. Neurochem Res. 2007;32:2194-2202. (Pubitemid 350059863)
35. Fukushima T, Takeshima H, Kataoka H. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res. 2009;29:4845-4854.